SINGAPORE -- To mark its 100th year of advancing cancer research, the American Association for Cancer Research is holding Centennial Conferences in North America, Europe, and Asia. The AACR has teamed with the Genome Institute of Singapore and Singapores Agency for Science, Technology and Research (A*STAR) to hold the first of these conferences from November 4 to 8 in Singapore: the AACR Centennial Conference on Translational Cancer Medicine: From Technology to Treatment.
The conference will convene cancer research experts, scientists in training, and physicians from academia, industry, and government in Singapore to discuss emerging technologies that will enable the translation of laboratory discoveries into the practice of cancer medicine.
This meeting will foster the necessary dialogue to speed application of breakthrough laboratory discoveries to the practice of medicine. Translational cancer medicine provides the tools to build the connections needed to move practical knowledge from the laboratory to drug development to patient care, said William N. Hait, M.D., Ph.D., president of AACR, co-chairperson of the conference and senior vice president and head, worldwide hematology oncology research and development at Johnson and Johnson. By hosting this meeting in Singapore, not only are we expanding this discussion across international lines, but we are also highlighting the unique strengths of our Singapore colleagues as well as the challenges faced by researchers in response to the needs of Asian patients.
Specific topics will include advanced studies in cancer biology, genomics and molecular targets for future cancer drugs as well as the latest imaging, and high-throughput approaches to cancer detection, diagnosis, and treatment. The meeting will also explore questions specific to the region, such as the constraints and opportunities of cancer care delivery in Asia, and how best to tailor cancer treatment to the genetic profile of tumors found among Asian populations.
The early years of the 21st century no doubt will go down in history as a turning point in our efforts to improve the prevention and treatment of cancer through knowledge gained in the laboratory, said Edison Liu, Ph.D., executive director of the Genome Institute of Singapore, one of the 14 research institutes in the A*STAR collaborative. Translational research has become one of the most exciting areas of science at every major biomedical institution, from Singapore to Boston to London.
|Contact: Staci Vernick Goldberg|
American Association for Cancer Research